NCT06365840View on ClinicalTrials.gov

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

August 31, 2029

Conditions
TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Interventions
DRUG

IMC-001

All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.

Trial Locations (1)

Unknown

RECRUITING

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

ImmuneOncia Therapeutics Inc.

INDUSTRY